(Q53901244)

22 May 2018

title

Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. (English)

1 reference

22 May 2018

0 references

0 references

1 reference

congestive heart failure

1 reference

Nieminen MS

1

1 reference

22 May 2018

Akkila J

2

1 reference

22 May 2018

Hasenfuss G

3

1 reference

22 May 2018

Kleber FX

4

1 reference

22 May 2018

Lehtonen LA

5

1 reference

22 May 2018

Mitrovic V

6

1 reference

22 May 2018

Nyquist O

7

1 reference

22 May 2018

Remme WJ

8

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 November 2000

1 reference

22 May 2018

Journal of the American College of Cardiology

published in

1 reference

22 May 2018

volume

36

1 reference

22 May 2018

issue

6

1 reference

22 May 2018

page(s)

1903-1912

1 reference

22 May 2018

The treatment of heart failure: The Task Force of the Working Group on Heart Failure of the European Society of Cardiology

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

New inotropic concepts: rationale for and differences between calcium sensitizers and phosphodiesterase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

Influence of isoproterenol and ouabain on excitation-contraction coupling, cross-bridge function, and energetics in failing human myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

Troponin C–Mediated Calcium Sensitization Induced by Levosimendan Does Not Impair Relaxation

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

Hemodynamic changes mimicking a vasodilator drug response in the absence of drug therapy after right heart catheterization in patients with chronic heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

Physiologic Assessment of Milrinone Therapy in Severe Heart Failure Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

The management of chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

Myocardial efficiency during calcium sensitization with levosimendan: A noninvasive study with positron emission tomography and echocardiography in healthy volunteers*

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900961-X

7 January 2021

10.1016/S0735-1097(00)00961-X

Identifiers

DOI

1 reference

22 May 2018

1 reference

22 May 2018